Immunovant Expects Brepocitinib Launch by End of September
Immunovant CEO Matthew Gline said the company expects to launch brepocitinib by the end of September, pending FDA action. The company also reported enrollment in a phase 3 cutaneous sarcoidosis study and outlined anticipated second-half data readouts.